Advertisement
Home »

GM-CSF-producing CCR2 CCR6 Th17 cells are pathogenic in DSS-induced colitis model in mice.

Jan 16, 2023

ABOUT THE CONTRIBUTORS

  • Shimpei Ariki

    Department of Infectious Disease Control, Oita University, Oita, Japan.

    Department of Gastroenterology, Oita University, Oita, Japan.

    Sotaro Ozaka

    Department of Infectious Disease Control, Oita University, Oita, Japan.

    Department of Gastroenterology, Oita University, Oita, Japan.

    Nozomi Sachi

    Department of Infectious Disease Control, Oita University, Oita, Japan.

    Thanyakorn Chalalai

    Department of Infectious Disease Control, Oita University, Oita, Japan.

    Yasuhiro Soga

    Department of Infectious Disease Control, Oita University, Oita, Japan.

    Chiaki Fukuda

    Department of Infectious Disease Control, Oita University, Oita, Japan.

    Yomei Kagoshima

    Department of Infectious Disease Control, Oita University, Oita, Japan.

    Department of Gastroenterology, Oita University, Oita, Japan.

    Supanuch Ekronarongchai

    Department of Infectious Disease Control, Oita University, Oita, Japan.

    Kazuhiro Mizukami

    Department of Gastroenterology, Oita University, Oita, Japan.

    Hospital Clinical Training Institute for Interns, Faculty of Medicine, Oita University, Oita, Japan.

    Naganori Kamiyama

    Department of Infectious Disease Control, Oita University, Oita, Japan.

    Kazunari Murakami

    Department of Gastroenterology, Oita University, Oita, Japan.

    Takashi Kobayashi

    Department of Infectious Disease Control, Oita University, Oita, Japan.

    Research Center for GLOBAL and LOCAL Infectious Diseases, Oita University, Oita, Japan.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement